Cognition Therapeutics, Inc. (CGTX) earnings
CGTX earnings moved a median of -2.67% by the close. Quarterly and annual CGTX reports and results, each read against the price at its own news timestamp. Back to the CGTX overview →
22 measured CGTX earnings events.
Where these CGTX earnings landedvs 22 measured CGTX earnings reactions
| Middle 50% of CGTX earnings reactions | -3.77% to -1.19% |
|---|---|
| Median reaction (to close) | -2.67% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 CGTX earnings events with a measured close landed between -3.77% and -1.19%; 23% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q COGNITION THERAPEUTICS For: Jun 30 | SEC filing · Form 10-Q | +1.82% | -1.82% | |
| Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update | Press release | +1.82% | -1.82% | |
| Form 10-Q COGNITION THERAPEUTICS For: Mar 31 | SEC filing · Form 10-Q | -0.43% | +3.42% | |
| Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update | Press release | -0.43% | +3.42% | |
| Form 10-K COGNITION THERAPEUTICS For: Dec 31 | SEC filing · Form 10-K | -1.79% | -3.57% | |
| Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs | Press release | +0.00% | -1.19% | |
| Form 10-Q COGNITION THERAPEUTICS For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -1.19% | |
| Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs | Press release | +3.76% | +11.68% | |
| Form 10-Q COGNITION THERAPEUTICS For: Jun 30 | SEC filing · Form 10-Q | +3.76% | +11.68% | |
| Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update | Press release | -4.10% | -8.58% | |
| Form 10-Q COGNITION THERAPEUTICS For: Mar 31 | SEC filing · Form 10-Q | -4.10% | -8.58% | |
| Form 10-K COGNITION THERAPEUTICS For: Dec 31 | SEC filing · Form 10-K | -4.25% | -9.21% | |
| Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update | Press release | -1.67% | -10.48% | |
| Form 10-Q COGNITION THERAPEUTICS For: Sep 30 | SEC filing · Form 10-Q | -1.67% | -10.48% | |
| Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update | Press release | +0.05% | -2.31% | |
| Form 10-Q COGNITION THERAPEUTICS For: Jun 30 | SEC filing · Form 10-Q | +0.05% | -2.31% | |
| Cognition Therapeutics to Report Second Quarter 2024 Financial Results | Press release | +1.71% | +11.20% | |
| Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update | Press release | -3.03% | -3.03% | |
| Form 10-Q COGNITION THERAPEUTICS For: Mar 31 | SEC filing · Form 10-Q | -3.03% | -3.03% | |
| Form 10-K COGNITION THERAPEUTICS For: Dec 31 | SEC filing · Form 10-K | +0.00% | -3.19% | |
| Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update | Press release | -4.46% | -3.77% | |
| Form 10-Q COGNITION THERAPEUTICS For: Sep 30 | SEC filing · Form 10-Q | -4.46% | -3.77% |
Keep exploring
More CGTX: analyst actions → · SEC filings → · CGTX overview →